Protagonist Therapeutics Files 8-K for Financial Results
Ticker: PTGX · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1377121
Sentiment: neutral
Topics: 8-K Filing, Financial Disclosure, Corporate Update
Related Tickers: PTGX
TL;DR
🚨 **Protagonist Therapeutics just filed an 8-K for financial results, details to follow!**
AI Summary
Protagonist Therapeutics, Inc. filed an 8-K on February 27, 2024, to report its results of operations and financial condition, along with related financial statements and exhibits. The filing indicates a standard disclosure of financial performance, but specific dollar amounts or detailed results are not provided within this initial filing snippet.
Why It Matters
This filing signals that Protagonist Therapeutics, Inc. is disclosing its latest financial performance, which is crucial for investors to assess the company's health and future prospects. While specific details are not in this snippet, the full filing would contain key data points.
Risk Assessment
Risk Level: medium — The filing itself is a standard regulatory disclosure; the actual risk depends entirely on the financial results contained within the full document, which are not provided here.
Key Numbers
- N/A — Financial Results (Specific financial results (e.g., revenue, net income) are not provided in this filing snippet.)
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — registrant
- United States Securities and Exchange Commission (company) — regulatory body
- Delaware (location) — state of incorporation
- February 27, 2024 (date) — date of report
- 7707 Gateway Blvd., Suite 140, Newark, CA 94560-1160 (location) — business address
- 001-37852 (other) — Commission File Number
- 98-0505495 (other) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing by Protagonist Therapeutics, Inc.?
The primary purpose is to report the company's results of operations and financial condition, and to file related financial statements and exhibits, as indicated by Item 2.02 and Item 9.01.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 27, 2024.
What is the state of incorporation for Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Protagonist Therapeutics, Inc.?
The Commission File Number for Protagonist Therapeutics, Inc. is 001-37852.
What type of industry does Protagonist Therapeutics, Inc. operate in, according to its SIC code?
According to its Standard Industrial Classification (SIC) code 2834, Protagonist Therapeutics, Inc. operates in the 'PHARMACEUTICAL PREPARATIONS' industry.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-02-27 16:12:36
Key Financial Figures
- $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
Filing Documents
- tm247315d1_8k.htm (8-K) — 27KB
- tm247315d1_ex99-1.htm (EX-99.1) — 80KB
- tm247315d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-028208.txt ( ) — 296KB
- ptgx-20240227.xsd (EX-101.SCH) — 3KB
- ptgx-20240227_lab.xml (EX-101.LAB) — 33KB
- ptgx-20240227_pre.xml (EX-101.PRE) — 22KB
- tm247315d1_8k_htm.xml (XML) — 4KB
02. Results of Operations
Item 2.02. Results of Operations and Financial Condition. On February 27, 2024, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release titled "Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update" is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated February 27, 2024, titled "Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: February 27, 2024 By: /s/ Asif Ali Asif Ali Chief Financial Officer